Clinical Trials Browser

NETWORK × Observational × tremelimumab × Clear all

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma